News

BenevolentAI announces $90 million investment from Temasek

New capital will accelerate scientific and product innovation and drive further scale of drug discovery and development platform.

London, September 17 2019: BenevolentAI, the leader in the creation and application of AI and machine learning to transform the way medicines are discovered and developed, today announces that it has raised $90 million from Temasek, a Singapore-headquartered investment company. Raine Advisors acted as exclusive financial advisors to BenevolentAI.  

BenevolentAI aims to improve the lives of patients suffering from diseases with no effective treatment. The Benevolent Platform® is used by scientists and technologists to find new ways to treat disease, improve the efficacy and lower the development time and costs of new treatments.  

The funding will be used to scale and further develop the Benevolent Platform for drug discovery and development. BenevolentAI will continue to advance its growing pipeline of internal drug development programmes and collaborations with strategic partners across its key therapeutic areas. Most recently, BenevolentAI announced long-term collaborations with AstraZeneca and Novartis, which will generate meaningful revenues for BenevolentAI over a multi-year period.

Joanna Shields, CEO of BenevolentAI, said: “We are pleased that Temasek has invested in us to support our mission to bring more effective medicines to the patients who need them. This year, we have demonstrated strong commercial and scientific progress and this funding will further scale our technology and support the development of our pipeline of potentially transformational medicines.”

The Benevolent Platform® is a leading computational and experimental drug discovery platform that enables scientists to uncover new ways to treat disease and personalise drugs for patients. It focuses on three key areas; target identification, molecular design and precision medicine, to better understand the underlying mechanisms of disease and to develop new treatments for the millions of patients who need them.



Notes to editors

For more information, please contact
press@benevolent.ai

About BenevolentAI

BenevolentAI, founded in 2013, is an AI company developing and applying advanced technologies to accelerate the journey from data to medicine. The company combines the power of computational medicine and advanced AI with the principles of open systems and cloud computing to transform the way drugs are designed, developed, tested and brought to market.  The company has developed the ‘Benevolent Platform’, the world’s only end-to-end computational and experimental platform for drug discovery that’s spans data ingestion to clinical development

BenevolentAI is HQ’d in London with a research facility in Cambridge (UK) and further offices in New York and Belgium. BenevolentAI has active R&D drug programmes from discovery to PhaseIIb in disease areas such as ALS, Parkinson’s, Ulcerative Colitis and Sarcopenia.

More Posts

You Might Also Like

News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022
News
BenevolentAI joins the World Economic Forum’s Global Innovators Community
BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.
Apr 21, 2022